{
    "organizations": [],
    "uuid": "a8ef0e4900b8a19d80103769fda36452e92aeab6",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-advisory-committee-votes-in-fa/brief-fda-advisory-committee-votes-in-favor-of-lucemyra-idUSFWN1R90SQ",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Advisory Committee Votes In Favor Of Lucemyra",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 27 (Reuters) -\n* FDA ADVISORY COMMITTEE VOTES IN FAVOR OF LUCEMYRA™ (LOFEXIDINE) FOR THE MITIGATION OF OPIOID WITHDRAWAL SYMPTOMS\n* US WORLDMEDS - IF APPROVED, LOFEXIDINE WILL BE MARKETED UNDER BRAND NAME LUCEMYRA​\n* US WORLDMEDS - FDA PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE VOTED 11 TO 1 TO RECOMMEND LOFEXIDINE APPROVAL FOR MITIGATING OPIOID WITHDRAWAL SYMPTOMS\n* US WORLDMEDS SAYS FDA HAS SET PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE FOR LUCEMYRA IN Q2 2018\n* US WORLDMEDS​ - ‍ADVISORY COMMITTEE’S DISCUSSIONS BASED ON CO’S NDA FOR LUCEMYRA Source text for Eikon:\n ",
    "published": "2018-03-28T04:20:00.000+03:00",
    "crawled": "2018-03-28T19:02:19.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "fda",
        "advisory",
        "committee",
        "vote",
        "favor",
        "lofexidine",
        "mitigation",
        "opioid",
        "withdrawal",
        "symptom",
        "u",
        "worldmeds",
        "approved",
        "lofexidine",
        "marketed",
        "brand",
        "name",
        "u",
        "worldmeds",
        "fda",
        "psychopharmacologic",
        "drug",
        "advisory",
        "committee",
        "voted",
        "recommend",
        "lofexidine",
        "approval",
        "mitigating",
        "opioid",
        "withdrawal",
        "symptom",
        "u",
        "worldmeds",
        "say",
        "fda",
        "set",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "pdufa",
        "target",
        "action",
        "date",
        "lucemyra",
        "q2",
        "u",
        "committee",
        "discussion",
        "based",
        "co",
        "nda",
        "lucemyra",
        "source",
        "text",
        "eikon"
    ]
}